Research of antisense oligonucleotide therapy for muscular dystrophy using knockout mouse as a model

以基因敲除小鼠为模型的反义寡核苷酸治疗肌营养不良症的研究

基本信息

  • 批准号:
    18591152
  • 负责人:
  • 金额:
    $ 2.53万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2006
  • 资助国家:
    日本
  • 起止时间:
    2006 至 2007
  • 项目状态:
    已结题

项目摘要

Duchenne muscular dystrophy (DMD) is the most common inherited muscular disease, and deletion mutations of the dystrophin gene that result in production of out-of-frame dystrophin mRNA have been identified in two-thirds of DMD cases. Transformation of an out-of-frame mRNA into an in-frame dystrophin message by inducing exon skipping and thereby enabling production of semi-functional internally deleted dystrophin is considered one of the approaches most likely to lead to success. We have reported that transfection of an antisense oligonucleotide that bind to a splicing enhancer sequence of exon 19 induced exon 19 skipping in cultured cells. Furthermore, intravenous infusion of the antisense oligonucleotide resulted in exon skipping in dystrophin mRNA and production of dystrophinmtein in muscle of DMD case with deletion of exon 20. Although an analysis of antisense oligonucleotide effect in DMD animal model is necessary for developing more effective strategy of this treatment, no DMD mod … More el mouse was not available. Unexpectedly, we can get the knockout mouse of dystrophin exon 52, then the effect of antisense oligonucleotide was analyzed using this model mouse.Because exon 52 of the dystrophin gene consists of 118 nucleotides, out-of-frame mRNA is produced in this model mouse. Induction of the skipping of exon 51 (233 bp) or exon 53 (212 bp) result in transformation of an out-of frame into an in-frame mRNA. Various antisense oligonucleotides against these exons were analyzed for activity inducing exon skipping and effective antisense oligonucleotides could be detected in each exon. And 4'-C-ethylene-bridged nucleic acids (ENA)/RNA chimera oligonucleotides which are more resistant against nucleases and more strongly bind to target sequences were used. In cultured myocyte of DMD model mouse transfection of the antisense oligonucleotide induced the skipping of each exon, and produced an in-frame dystrophin mRNA. Furthermore, these oligonucleotides could be administered intravenously and intraperitoneally to model mouse without any adverse events. Less
杜氏肌营养不良症(DMD)是最常见的遗传性肌肉疾病,并且在三分之二的DMD病例中已经鉴定出导致框外肌营养不良蛋白mRNA产生的肌营养不良蛋白基因的缺失突变。通过诱导外显子跳跃将框外mRNA转化为框内肌营养不良蛋白信息,从而能够产生半功能性内部缺失的肌营养不良蛋白,被认为是最有可能导致成功的方法之一。我们已经报道,转染的反义寡核苷酸,结合剪接增强子序列的外显子19诱导外显子19跳跃培养细胞。此外,静脉输注反义寡核苷酸导致dystrophin mRNA中的外显子跳跃,并在外显子20缺失的DMD病例的肌肉中产生dystrophin蛋白。尽管分析反义寡核苷酸在DMD动物模型中的作用对于开发更有效的治疗策略是必要的,但没有DMD模型, ...更多信息 el鼠标不可用。结果获得了dystrophin基因外显子52的敲除小鼠,并以此为模型分析了反义寡核苷酸的作用,由于dystrophin基因外显子52由118个核苷酸组成,因此在该模型小鼠中产生了框外mRNA。外显子51(233 bp)或外显子53(212 bp)跳跃的诱导导致框外mRNA转化为框内mRNA。分析针对这些外显子的各种反义寡核苷酸诱导外显子跳跃的活性,并且可以在每个外显子中检测到有效的反义寡核苷酸。并且使用了对核酸酶更具抗性并且更强地结合靶序列的4 ′-C-乙烯桥连核酸(ENA)/RNA嵌合体寡核苷酸。在培养的DMD模型小鼠心肌细胞中,反义寡核苷酸转染诱导了每个外显子的跳跃,并产生了符合读框的dystrophin mRNA。此外,这些寡核苷酸可以静脉内和腹膜内施用至模型小鼠而没有任何不良事件。少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Identification of seven novel cryptic exons embedded in the dystrophin gene and characterization of 14 cryptic dystrophin exons
嵌入肌营养不良蛋白基因中的 7 个新型隐性外显子的鉴定以及 14 个隐性肌营养不良蛋白外显子的表征
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Habara;Y;Zhang Z
  • 通讯作者:
    Zhang Z
A nonsense mutation-created intraexonic splice site is active in the lymphocytes, but not in the skeletal muscle of a DMD patient. Human Genetics 120 737-42 2007
无义突变产生的外显子内剪接位点在淋巴细胞中活跃,但在 DMD 患者的骨骼肌中不活跃。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tran;VK
  • 通讯作者:
    VK
Novel cryptic exons identified in introns 2 and 3 of the human dystrophin gene with duplication of exons 8-11.
在人类肌营养不良蛋白基因的内含子 2 和 3 中鉴定出新的隐秘外显子,其中外显子 8-11 重复。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Takeshima;Y;Katayama Y.;Takeshima Y;Tran VK;Ishibashi K
  • 通讯作者:
    Ishibashi K
Idcntification of seven novel cryptic exons embedded in the dystrophin gene and characterization of 14 cryptic dystrophin exons.
鉴定嵌入肌营养不良蛋白基因中的 7 个新型隐性外显子,并表征 14 个隐性肌营养不良蛋白外显子。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tran;VK;Zhang Z
  • 通讯作者:
    Zhang Z
Co-occurrence of mutations in both dystrophin- and androgen-receptor genes is a novel cause of female Duchenne muscular dystrophy
  • DOI:
    10.1007/s00439-006-0159-4
  • 发表时间:
    2006-06-01
  • 期刊:
  • 影响因子:
    5.3
  • 作者:
    Katayama, Y;Tran, VK;Matsuo, M
  • 通讯作者:
    Matsuo, M
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAKESHIMA Yasuhiro其他文献

TAKESHIMA Yasuhiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAKESHIMA Yasuhiro', 18)}}的其他基金

Investigation of fibrotic factors during the exon-skipping therapy using antisense oligonucleotide for muscular dystrophy
使用反义寡核苷酸治疗肌营养不良症的外显子跳跃疗法期间纤维化因素的研究
  • 批准号:
    23591495
  • 财政年份:
    2011
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research of signal transduction system in antisense therapy for muscular dystrophy
信号转导系统在反义治疗肌营养不良症中的研究
  • 批准号:
    20591223
  • 财政年份:
    2008
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research of novel treatment for childhood leukemia by disrupting the chimeric gene function using RNAi
利用 RNAi 破坏嵌合基因功能治疗儿童白血病的新方法研究
  • 批准号:
    16591027
  • 财政年份:
    2004
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular genetic study on maple syrup urine disease in Philippines
菲律宾枫糖浆尿病的分子遗传学研究
  • 批准号:
    14406023
  • 财政年份:
    2002
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Prevention of developmental disorders of intra-uterine growth retarded infants with growth factors.
使用生长因子预防子宫内生长迟缓婴儿的发育障碍。
  • 批准号:
    14571048
  • 财政年份:
    2002
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research for the exonic splicing enhancer sequences in dysttrophin gene
肌营养不良蛋白基因外显子剪接增强子序列的研究
  • 批准号:
    13670802
  • 财政年份:
    2001
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanistic study of Small-molecular Therapy in diabetic Wound Healing
小分子治疗糖尿病伤口愈合的机制研究
  • 批准号:
    10366031
  • 财政年份:
    2021
  • 资助金额:
    $ 2.53万
  • 项目类别:
Mechanistic study of Small-molecular Therapy in diabetic Wound Healing
小分子治疗糖尿病伤口愈合的机制研究
  • 批准号:
    10569598
  • 财政年份:
    2021
  • 资助金额:
    $ 2.53万
  • 项目类别:
Development of Molecular Therapy for Esophageal and Gastric Cancer Based on Cancer Host Linkage Regulation by Analysis of Exosomes and Intestinal Microbiota
通过分析外泌体和肠道微生物群,开发基于癌症宿主连锁调节的食管癌和胃癌分子治疗
  • 批准号:
    20H03749
  • 财政年份:
    2020
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular pathogenesis and molecular therapy in RUNX1-EVI1-type leukemia.
RUNX1-EVI1型白血病的分子发病机制和分子治疗。
  • 批准号:
    19K08822
  • 财政年份:
    2019
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A new molecular therapy using (pro)Renin Receptor for gliomas
使用(原)肾素受体治疗神经胶质瘤的新分子疗法
  • 批准号:
    18H02913
  • 财政年份:
    2018
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The development of novel molecular therapy targeting to carcinoma- stroma interaction and heterogeneity of advanced pancreatic cancer.
针对晚期胰腺癌的癌间质相互作用和异质性的新型分子疗法的发展。
  • 批准号:
    18K07981
  • 财政年份:
    2018
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Heat Activated Liposomal Delivery of Chemo and Molecular Therapy in Combination with Radiotherapy for Treatment of Breast Cancer Recurrence at the Chest Wall
热激活脂质体递送化疗和分子疗法联合放疗治疗乳腺癌胸壁复发
  • 批准号:
    369901
  • 财政年份:
    2017
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Operating Grants
Molecular therapy for esophageal cancer targeting the p53 and the Hippo pathways
针对 p53 和 Hippo 通路的食管癌分子治疗
  • 批准号:
    17K10617
  • 财政年份:
    2017
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel molecular therapy targeting aberrant glycogen synthase kinase-3 beta in soft tissue sarcoma
针对软组织肉瘤异常糖原合酶激酶 3 β 的新型分子疗法
  • 批准号:
    16K20040
  • 财政年份:
    2016
  • 资助金额:
    $ 2.53万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了